AtriCure Initiates BoxX-NoAF Trial to Prevent Post-Operative Atrial Fibrillation in Cardiac Surgery Patients
核心洞察
AtriCure has enrolled the first patient in the BoxX-NoAF clinical trial, evaluating combined surgical ablation and left atrial appendage (搜索) exclusion to prevent new-onset atrial fibrillation (搜索) after cardiac surgery.
Post-operative atrial fibrillation (搜索) affects up to 50% of cardiac surgery patients and is associated with increased mortality, stroke (搜索) risk, and hospital costs.
The randomized controlled trial will enroll up to 960 subjects at 75 sites worldwide and represents the first study designed to demonstrate superiority of this combined approach over no treatment.
AtriCure, Inc. has announced the enrollment and treatment of the first patient in the BoxX-NoAF clinical trial, marking a significant milestone in efforts to prevent post-operative atrial fibrillation (搜索) (POAF) in cardiac surgery patients. The first patient was treated by Dr. Anthony Rongione, Cardiothoracic Surgeon at Orlando Health Heart and Vascular Institute (搜索) in Orlando, Florida.
Addressing a Critical Surgical Complication
Post-operative atrial fibrillation (搜索) represents the most common complication following cardiac surgery, occurring in as many as 50% of patients and presenting either immediately or in the months following surgery. These arrhythmias are associated with increased mortality, morbidity, cerebrovascular accidents, atrial fibrillation (搜索) recurrence, extended hospital length of stay, and elevated total hospital costs.
"POAF remains one of the most challenging complications for patients who have undergone cardiac surgery, undermining patient recovery and consuming significant hospital resources," said Edward G. Soltesz, MD, MPH, Cleveland Clinic cardiovascular and thoracic surgeon. "We believe the BoxX procedure, combining a box lesion and LAA exclusion, could meaningfully lower the occurrence of new-onset Afib and significantly improve the quality of care for these patients."
Trial Design and Scope
The Box Lesion Creation with Left Atrial Appendage (搜索) Exclusion to Reduce the Occurrence of New-onset Atrial Fibrillation (搜索) (BoxX-NoAF) clinical trial (NCT06989775) is a prospective, multicenter, randomized, FDA-approved investigational device exemption (IDE) study. The trial will enroll up to 960 subjects at up to 75 sites worldwide, evaluating the safety and effectiveness of the AtriCure Isolator® Synergy™ EnCompass® clamp and AtriClip® Left Atrial Appendage Exclusion System.
This represents the first randomized controlled trial designed to demonstrate superiority of concomitant surgical ablation with left atrial appendage (搜索) management for reducing the occurrence of new-onset atrial fibrillation (搜索) compared to no treatment. The seminal trial will ultimately define clinical practice and treatment guidelines for reducing the occurrence of POAF and longer-term clinical atrial fibrillation in elevated risk cardiac surgery patients.
Strategic Implications
"The BoxX-NoAF trial, together with our LeAAPS trial that completed enrollment in July 2025, reflects AtriCure's vision to advance standards of care by expanding the benefits of surgical ablation and LAA exclusion to a broader population of cardiac surgery patients," said Michael Carrel, President and Chief Executive Officer. "We expect results of these trials to demonstrate that use of AtriCure devices can safely and effectively improve outcomes for cardiac surgery patients worldwide by reducing the prevalence of new-onset Afib, stroke (搜索), and systemic embolization."
If successful, trial results would position AtriCure to pursue expanded labeling for the EnCompass clamp and AtriClip systems when used together in a BoxX procedure, potentially making them the only FDA-approved devices for the prevention of post-operative and longer-term clinical atrial fibrillation (搜索).
Market Context
Atrial fibrillation (搜索) affects more than 59 million people worldwide. AtriCure's Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent and long-standing persistent atrial fibrillation, while the company's AtriClip® Left Atrial Appendage (搜索) Exclusion System products are the most widely sold LAA management devices worldwide.